Abstract:The accurate quantitative determination of affinity and binding kinetics (BK) for tight binding inhibition is extraordinary important from both the continuous optimization of compounds, particularly in developing structure–activity relationships (SAR), and the prediction of in vivo target occupancy (TO). Due to the unique properties for tight binding inhibition that the inhibitors are characterized by the ultrahigh-affinity, relatively fast association to the target enzyme combined with extremely slow dissociation of the inhibitor-enzyme binary complex, the classical steady state equilibrium methods are no longer valid. Here, we made several recommendations of how to design the optimal experiments and apply special mathematical calculation approaches to quantitatively evaluate the accurate affinity and BK as the examples of two tight binding inhibitors against the xanthine oxidase (XO), as well as compared the differences in the results calculated from the different data analytical methods and analyzed the influence of these differences on the XO engagement in human. Analysis of the results displayed that the accurate apparent dissociation constant (Ki*, app) was 0.2 ± 0.06 nM for topiroxotstat and was 0.45 ± 0.2 nM for febuxostat; that on-rate (kon) was (4.3 ± 1.1) × 106 M−1s−1 for topiroxotstat and was(133.3 ± 3.5) × 106 M−1s−1 for febuxostat, and off-rate (koff) was (1.0<math>±</math>0.2) × 10−5 s−1 for topiroxotstat and was ≤ 0.16 × 10−5 s−1for febuxostat. Moreover, there were significant differences in the Ki*, app and koff values estimated using the appropriate specialized methods for tight binding inhibition versus classical steady state equilibrium methods, with the substantial differences of 14-fold and 32-fold reduction for topiroxostat, respectively, and of 9.6-fold and ≥ 213-fold reduction for febuxostat, while the kon values remain the moderate differences for the two inhibitors. The obvious greater AUC of XO engagement time courses and longer durations of above 70% engagement by the appropriate specialized methods for tight binding inhibition were observed that the results display the differences of 70.1% and 88%, respectively for topiroxostat and of 38.1% and 35.0%, respectively for febuxostat in human liver cell than by classical steady state equilibrium methods. Again, our studies provide several valuable recommendations of the optimal experiment protocols and appropriate analytical approaches for accurately quantitatively assessing the affinity and BK parameters as well as demonstrate the ability of our recommended methods to generate reliable data for tight binding inhibitors against XO.

The Relationship between Xanthine Oxidoreductase and Xanthine Oxidase Activities in Plasma and Kidney Dysfunction

Relationship between Xanthine Oxidoreductase Redox and Oxidative Stress among Chronic Kidney Disease Patients

A Newly Developed Method-Based Xanthine Oxidoreductase Activities in Various Human Liver Diseases

Plasma Xanthine Oxidase Activity Is Predictive of Cardiovascular Disease in Patients with Chronic Kidney Disease, Independently of Uric Acid Levels

Plasma Xanthine Oxidoreductase Activity Associated with Glycemic Control in Patients with Pre-Dialysis Chronic Kidney Disease

Association between Plasma Xanthine Oxidoreductase Activity and the Renal Function in a General Japanese Population: The Tohoku Medical Megabank Community-Based Cohort Study

Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study

Comprehensive analysis of the relationship between xanthine oxidoreductase activity and chronic kidney disease

Emerging Roles of Xanthine Oxidoreductase in Chronic Kidney Disease

Prognostic impact of plasma xanthine oxidoreductase activity in patients with heart failure with atrial fibrillation

Xanthine oxidoreductase and metabolic syndrome

Xanthine oxidoreductase activity is correlated with hepatic steatosis

Which is more important, xanthine oxidase activity or uric acid itself, in the risk for cardiovascular disease?

Interplay between the Redox System and Renal Tubular Transport

Association of plasma xanthine oxidoreductase activity with vascular endothelial function independent of serum uric acid level: MedCity21 health examination registry

Accurate quantitative determination of affinity and binding kinetics for tight binding inhibition of xanthine oxidase

Metabolomics analysis elucidates unique influences on purine / pyrimidine metabolism by xanthine oxidoreductase inhibitors in a rat model of renal ischemia-reperfusion injury

Analysis of Purine Metabolism to Elucidate the Pathogenesis of Acute Kidney Injury in Renal Hypouricemia

Chronic kidney disease: Which role for xanthine oxidoreductase activity and products?

Xanthine oxidoreductase activity correlates with vascular endothelial dysfunction in patients with type 1 diabetes

Manganese Superoxide Dismutase Dysfunction and the Pathogenesis of Kidney Disease